There are two conventional treatments for clinically resectable rectalcancer. The first is surgery followed by postoperative combinedmodalitytherapy if the tumor is T3 and/or N1/2. The second, if thetumor is ultrasound T3 or clinical T4, is preoperative combined-modalitytherapy followed by surgery and postoperative chemotherapy. Thereare a number of new chemotherapeutic agents that have been developedfor the treatment of colorectal cancer. Phase I/II trials are examiningthe use of new chemotherapeutic agents in combination with pelvicradiation therapy, most commonly in the preoperative setting. Thereis considerable interest in integrating irinotecan (Camptosar) into preoperativecombined-modality therapy regimens for rectal cancer. Basedon these trials, the recommended regimen for patients who receiveirinotecan-based combined-modality therapy is continuous infusionfluorouracil (5-FU), irinotecan, and pelvic radiation. New trials examiningpreoperative combined-modality therapy regimens substitutingcapecitabine (Xeloda) for continuous infusion 5-FU are in progress.
There are two conventional treatments for clinically resectable rectal cancer. The first is surgery followed by postoperative combinedmodality therapy if the tumor is T3 and/or N1/2. The second, if the tumor is ultrasound T3 or clinical T4, is preoperative combined-modality therapy followed by surgery and postoperative chemotherapy. There are a number of new chemotherapeutic agents that have been developed for the treatment of colorectal cancer. Phase I/II trials are examining the use of new chemotherapeutic agents in combination with pelvic radiation therapy, most commonly in the preoperative setting. There is considerable interest in integrating irinotecan (Camptosar) into preoperative combined-modality therapy regimens for rectal cancer. Based on these trials, the recommended regimen for patients who receive irinotecan-based combined-modality therapy is continuous infusion fluorouracil (5-FU), irinotecan, and pelvic radiation. New trials examining preoperative combined-modality therapy regimens substituting capecitabine (Xeloda) for continuous infusion 5-FU are in progress.
There are two conventional treatments for clinically resectable rectal cancer. The first is surgery followed by postoperative combined- modality therapy if the tumor is T3 and/or N1/2. The second, if the tumor is ultrasound T3 or clinical T4, is preoperative combined-modality therapy followed by surgery and postoperative chemotherapy. Postoperative TherapyRationale and Results
The National Cancer Institute Consensus Conference concluded that combined-modality therapy was the standard postoperative adjuvant treatment for patients with T3 and/or N1/2 disease. Pelvic radiation therapy decreases local recurrence but does not improve survival. As would be predicted, randomized data do not reveal a survival advantage of pelvic radiation plus elective para-aortic and liver radiation vs pelvic radiation alone. The standard design is to deliver six cycles of chemotherapy with concurrent radiation during cycles 3 and 4. A randomized trial by Lee et al suggests that radiation should start with cycle 1 rather than cycle 3. However, since a number of patients did not receive the treatment arm to which they were randomized, further data are needed before recommending a change in sequence. For patients treated with postoperative combined-modality therapy who received fluorouracil (5-FU) as a single agent, there was a 10% survival advantage with continuous infusion (CI) 5-FU vs bolus 5-FU. The INT 0144 postoperative adjuvant rectal trial reported results at the American Society of Clinical Oncology (ASCO) 2003 annual meeting. Patients were randomized to three arms: (1) bolus 5-FU → CI 5-FU/radiation therapy (RT) → bolus 5-FU; (2) CI 5-FU → CI 5-FU/RT → CI 5-FU; (3) bolus 5- FU/leucovorin/levamisole (Ergamisol) → bolus 5-FU/leucovorin/ levamisole/RT → bolus 5-FU/leucovorin/ levamisole. There was a significant decrease in grade 3+ hematologic toxicity in arm 2; however, there was no significant difference in 3-year survival. Local control data were not reported. Given these results, CI 5-FU with radiation is recommended, and either arm 1 or 2 is a reasonable choice. If arm 1 is chosen, the bolus chemotherapy segment should be the Roswell Park regimen (weekly) rather than the Mayo Clinic regimen (monthly). The INT 0114 trial revealed that with longer follow-up the results are not as favorable. With a median follow-up of 7.4 years, the 7-year local failure rate was 17% and the survival rate was 56%. Patients with high-risk (T3, N+ or T4) disease have lower survival rates than those with lower-risk (T1/2, N+ or T3, N0) disease (45% vs 70%). There is an increase in acute toxicity associated with this improvement in local control and survival with postoperative combined-modality therapy. For example, the incidence of grade 3+ toxicity in the combinedmodality arms of the Gastrointestinal Tumor Study Group and Mayo/North Central Cancer Treatment Group (NCCTG) 79-47-51 trials was 25% to 50%. Furthermore, the percentages of patients finishing the prescribed six cycles of chemotherapy in those trials were only 65% and 50%, respectively. Retrospective data suggest that the acute toxicity with preoperative combined- modality therapy may be less than in the postoperative setting. The randomized German trial of preoperative vs postoperative combinedmodality therapy trial has confirmed these data.[9,10] Do All Patients Require Postoperative Adjuvant Therapy?
There are retrospective data that suggest there may be a subset of patients with T3, N0 disease who may not require adjuvant therapy, as well as patients with stage I disease who should be considered for adjuvant therapy. Retrospective trials examining patients at both Massachusetts General Hospital and Memorial Sloan-Kettering Cancer Center have identified favorable subsets of patients with T3, N0 disease who, following surgery alone, had a 10-year actuarial local recurrence rate of < 10%. In addition to such other modifications as smooth nodules in the fat being staged as node positive and irregular nodules as vascular invasion (VI is microscopic and VI2 is macroscopic), the 6th edition of the American Joint Committee on Cancer staging system subdivides stage III into IIIA (T1/2, N1), IIIB (T3/4, N1), and IIIC (any T, N2). The prognostic validity of this change was supported by both the pooled analysis of Intergroup and National Surgical Adjuvant Breast and Bowel Project (NSABP) postoperative trials and the retrospective analysis of the American College of Surgeons National Cancer database. The 5-year survival of stages IIIA, IIIB, and IIIC in the pooled analysis was 81%, 57%, and 49%, respectively, and in the National Cancer database it was 55%, 35%, and 25%, respectively. Based on 5-year survival data, radiation does not improve the results of chemotherapy alone in stages T3, N0 and T1/2, N1 disease. However, local control data are needed before recommending chemotherapy alone for this subset of patients. Preoperative TherapyRationale
Preoperative therapy (most commonly combined-modality therapy) has gained acceptance as a standard adjuvant therapy. The potential advantages of the preoperative approach include decreased tumor seeding, less acute toxicity, increased radiosensitivity due to more oxygenated cells, and enhanced sphincter preservation.[ 2] The primary disadvantage of preoperative radiation therapy is possibly overtreating patients with either early-stage (T1/2, N0) or undetected metastatic disease. However, the imaging techniques discussed above allow more accurate selection, thereby decreasing the number of patients who are overtreated. Retrospective data suggest that pre- operative combined-modality therapy increases pathologic downstaging compared with preoperative radiation without chemotherapy and is associated with a lower incidence of acute toxicity compared with postoperative combined-modality therapy.[ 8] In general, the incidence of grade 3+ acute toxicity during the combined-modality segment is 15% to 25%, the complete response rates are 10% to 30% pathologic and 10% to 20% clinical, and the incidence of local recurrence is 0% to 10%. The recently completed randomized European Organization for Research and Treatment of Cancer (EORTC) trial 22921 is addressing whether preoperative combinedmodality therapy is more effective than preoperative radiation therapy, and if the postoperative chemotherapy component is necessary. The preliminary results reveal an increase in the pathologic complete response (pCR) rate in those patients receiving chemotherapy concurrent with radiation.[16a] The local control and survival rates are pending. There are 12 modern randomized trials of preoperative radiation therapy (without chemotherapy) for clinically resectable rectal cancer. All use low to moderate doses of radiation. Overall, most of the trials showed a decrease in local recurrence, and in five trials this difference reached statistical significance. Although in some trials a subset analysis has revealed a significant improvement in survival, the Swedish Rectal Cancer Trial is the only one that reported a survival advantage for the total treatment group. Two meta-analyses report conflicting results. While both reveal a decrease in local recurrence, the analysis by Camma et al reported a survival advantage whereas the analysis by the Colorectal Cancer Collaborative Group did not. Intensive Short-Course Preoperative Radiation
The Swedish Rectal Cancer Trial is the only randomized trial of preoperative radiation therapy to report a significant improvement in survival. Patients with clinically resectable (T1-3) rectal cancer were random- ized to receive 25 Gy in 1 week followed by surgery 1 week later vs surgery alone. Those who received preoperative radiation had a significant decrease in local recurrence (12% vs 27%) and a corresponding improvement in 5-year survival (58% vs 48%). It is important to analyze these positive results in the context of the rest of the literature. First, given that the other 11 randomized trials of preoperative radiation therapy do not report a survival benefit, these data clearly need to be confirmed by additional studies. The most recent trial to report results was the Dutch CKVO 95-04 trial, which randomized 1,805 patients with clinically resectable (T1-3) disease to surgery alone (with a total mesorectal excision [TME]) or intensive short-course preoperative radiation followed by TME. Although radiation significantly decreased local recurrence (8% vs 2%), there was no difference in 2-year survival (82%). With longer follow-up, 5-year local failure was higher with TME (12%); however, it was still significantly decreased (to 6%) with preoperative radiation. Second, even if future trials confirm a survival benefit, there are other equally important end points in rectal cancer that need to be addressed. These include acute toxicity, sphincter preservation and function, and quality of life. For example, acute toxicity in the Dutch CKVO 95-04 trial included 10% neurotoxicity, 29% perineal wound complications, and 12% postoperative leaks. In the patients who developed postoperative leaks, 80% required surgery resulting in 11% mortality. The presence of a positive circumferential margin is an important sign of negative prognosis. In the Dutch CKVO trial, 17% of patients had positive circumferential margins; they received 50 Gy postoperatively. Postoperative radiation did not compensate for positive margins. Unfortunately, few centers in the United States perform the necessary pathologic examination to detect positive circumferential margins. Data from Beets-Tan et al suggest that preoperative magnetic resonance imaging can identify patients who will have positive margins and can be used to better select patients for preoperative therapy. It is not possible to compare accurately the local control and survival results of intensive short-course radiation with conventional preoperative combined-modality therapy. This is because of selection bias in favor of the series using intensive short-course radiation. The conventional preoperative combined-modality therapy regimens are limited to patients with clinical T3 disease, whereas most trials that use intensive short-course preoperative radiation include patients with clinical T1-3 disease. Sphincter Preservation With Preoperative Radiation
A major goal of preoperative therapy is sphincter preservation. From this viewpoint, the advantage of preoperative therapy is to decrease the volume of the primary tumor. When the tumor is located in close proximity to the dentate line, this decrease in tumor volume may allow the surgeon to perform a sphincter-conserving procedure that would not otherwise be possible. However, if the tumor directly invades the anal sphincter, sphincter preservation is unlikely even when a complete response is achieved. One of the most important controversies with preoperative therapy is whether the degree of downstaging is adequate to enhance sphincter preservation. Furthermore, if preoperative radiation therapy is effective, what regimen (intensive short course vs conventional course) is preferred? An analysis of 1,316 patients treated on two previously published Scandinavian trials of intensive shortcourse radiation revealed that downstaging was most pronounced when the interval between the completion of radiation and surgery was at least 10 days. In the Dutch CKVO 95- 04 trial, where the interval was 1 week, there was no downstaging. None of the other randomized trials of intensive short-course preoperative radiation address the issue of sphincter preservation, and it is not an end point of the trials. When the goal of preoperative therapy is sphincter preservation, conven- tional doses and radiation techniques are recommended. These include multiple- field techniques to a total dose of 45 to 50.4 Gy at 1.8 Gy/fraction. Surgery should be performed 4 to 7 weeks following completion of radiation. Unlike the intensive short-course radiation regimen, this conventional design allows for two important events to occur: first is the recovery from the acute side effects of radiation, second is adequate time for tumor downstaging. Data from the Lyon R90-01 trial of preoperative radiation suggest that an interval > 2 weeks following completion of radiation increases the chance of downstaging. It is not known whether increasing the interval between the end of intensive shortcourse radiation and surgery to ≥ 4 weeks will increase downstaging. This question is being addressed in an ongoing randomized trial from Sweden (Stockholm III trial). Preoperative Prospective Clinical Assessment
The most accurate method with which to determine if preoperative therapy increases sphincter preservation is to perform a prospective clinical assessment. In this setting, the operating surgeon examines the patient prior to the start of preoperative therapy and declares the type of operation required. It should be noted that this assessment is based on an office examination and may not accurately reflect the assessment when the patient is relaxed under general anesthesia. The only way to account for this potential bias is to perform a randomized trial of preoperative vs postoperative therapy. The results of the German CAO/ARO/AIO 94 randomized trial of preoperative vs postoperative combined-modality therapy suggest that this assessment is accurate in 80% of cases.[9,28] Clinical Experience With Sphincter Preservation
There are eight phase I/II trials that have reported results in patients with clinically resectable rectal cancer who underwent a prospective clinical assessment by their surgeon prior to the start of preoperative therapy and were declared to need an abdominoperineal resection. All use conventional doses and radiation therapy techniques. Three use radiation therapy alone[27,29,30] and four use combined- modality therapy.[31-35] The incidence of sphincter preservation is only 23% in the NSABP series and 44% in the Lyon series. In the remaining five series it is approximately 70%. A valid concern of surgeons is that in order to perform sphincter preservation in those patients who would otherwise require abdominoperineal resection, the distal resection margin may be suboptimal (≤ 1 cm). Can preoperative therapy compensate for this? Retrospective data from Moore et al reveal that with preoperative combined modality therapy, the 3-year local control rates were similar regardless of whether the margins were > 2 cm, < 2 cm, > 1 cm, or < 1 cm, provided they were negative. Sphincter preservation without good function is of questionable benefit. In a series of 73 patients who underwent surgery, Grumann and associates reported that the 23 patients who underwent an abdominoperineal resection had a more favorable quality of life compared with the 50 who underwent a low anterior resection.[ 37] Although preoperative combinedmodality therapy may adversely effect sphincter function, the impact is most likely less than postoperative combined-modality therapy. In the four of eight preoperative series discussed above that report functional outcome, the majority (approximately 75%) have good to excellent sphincter outcome. Functional results continue to improve up to 1 year after surgery. Three randomized trials of preoperative vs postoperative combinedmodality therapy for clinically resectable T3 rectal cancer have been performed. Two are from the United States (INT 0147, NSABP R0-3) and one is from Germany (CAO/ARO/ AIO 94). All three use conventional doses and radiation therapy techniques and concurrent 5-FU-based chemotherapy, and all require a preoperative clinical assessment declaring the type of operation required. Unfortunately, low accrual has resulted in early closure of both the NSABP R-03 and INT 0147 trials. A preliminary report of the NSABP R-03 trial (with a median follow-up of 3 years) revealed that patients who received preoperative therapy had a lower local failure rate (5% vs 9%) and higher survival (85% vs 78%); however, neither reached statistical significance. The German trial completed the planned accrual of over 800 patients and randomized patients with T3/4 and/or N+ rectal cancers ≤16 cm from the anal verge to preoperative combined- modality therapy (with CI 5-FU) vs postoperative combined modality therapy. In order to help remove surgical bias, patients were stratified by surgeon. Compared with postoperative combined-modality therapy, patients who receive preoperative therapy had a significant decrease in local failure (6% vs 12%, P = .006), acute toxicity (28% vs 40%, P = .005), chronic toxicity (10% vs 23%, P = .04), and in those 194 patients judged by the surgeon to require and APR, a significant increase in sphincter preservation.(39% vs 20%, P = .004). With a median follow- up of 40 months there was no difference in 5-year survival (74%). Given the improved local control, acute and long term toxicity profile, and sphincter preservation reported in the German trial, patients with T3 rectal cancer who require combined modality therapy should receive it preoperatively. Predicting the Response of the Primary Tumor
Although some series show no correlation,[ 39,40] most suggest that there is improved outcome with increasing pathologic response to preoperative therapy.[41-47] Analyses of biopsies examining selected molecular markers such as c-K-ras, thymidylate synthase, p27kip1, p53,[51-54] apoptosis,[55,56] deleted in colorectal cancer gene, epidermal growth factor receptor, TP53, and Ki-67 have had varying success in helping to select patients who may best respond to preoperative therapy. Since all of the stud- ies are limited retrospective trials and most do not examine multiple markers, the need for adjuvant therapy should still be based solely on T and N stage at this time. Fortunately the new Intergroup rectal trials will prospectively collect tissues for these and other markers. Novel Combined-Modality RegimensIntroduction
There are a number of new chemotherapeutic agents that have been developed for the treatment of colorectal cancer patients. Phase I/II trials are examining the use of new chemotherapeutic agents in combination with pelvic radiation therapy, most commonly in the preoperative setting. Selected agents include UFT (uracil and tegafur), raltitrexed (Tomudex), oxaliplatin (Eloxatin),[ 61-65] irinotecan (Camptosar),[ 66] gefitinib (Iressa), and capecitabine (Xeloda)with pelvic radiation therapy. Combinations of new agents such as C225 with irinotecan in patients in advanced colorectal cancer are under development. This and other new chemotherapeutic agents will likely be combined with pelvic radiation in the future. Phase III trials are needed to determine if these regimens offer an advantage over those with 5-FU-based combined- modality therapy. Irinotecan-Based Regimens
Based on the significant survival advantage of irinotecan/5-FU/leucovorin vs 5-FU/leucovorin or irinotecan alone in patients with metastatic colorectal cancer, there is considerable interest in integrating irinotecan into preoperative combinedmodality therapy regimens for rectal cancer. There are a number of phase I or II trials combining irinotecan with radiation therapy. They use irinotecan either as monotherapy with oncea- day radiation or hyperfractionated radiation,[72,73] or more commonly in combination with bolus or CI 5-FU.[35,66,74-77] A phase I trial of escalating doses of weekly irinotecan (8 to 13 mg/m2 daily) weeks 1, 2, 4, and 5 plus con current 50.4 Gy in 28 patients with T3/4 rectal cancer was reported by Minsky et al. Of the 16 patients treated at the recommended dose level of 10 mg/m2, the pathologic complete response rate was 5% and the grade 3+ acute toxicity rate was 29%. Since these results were inferior to prior regimens tested at Memorial Sloan-Kettering, this irinotecan-alone regimen was not brought into phase II study. The other trial using irinotecan alone with preoperative radiation was reported by Volter and colleagues from Lausanne.[72,73] Twenty patients with T3/4 rectal cancer were entered in this phase I trial. Irinotecan was escalated from 30 to 105 mg/m2 weekly * 3 and hyperfractionated radiation (1.6 Gy bid to 41.6 Gy) began on week 2. The high incidence of anastomotic leak and/or abscess (30%) may have been related, in part, to the hyperfractionated radiation. The recommended dose level of irinotecan was 90 mg/m2. The remaining trials added CI 5-FU to the preoperative radiation/irinotecan combination. Klautke and associates from the University of Rostock performed a phase II trial in 26 patients with a variety of stages of rectal cancer. Doses were fixed: irinotecan (40 mg/m2 weekly), CI 5-FU (250 mg/m2/d), and radiation therapy (50.4 Gy). The incidence of grade 3+ toxicity was 15% hematologic and 35% diarrhea. In the 15 patients who underwent surgery, the response rates were 26% pathologic and 26% clinical. Even higher complete response rates were reported in a phase II trial from Mehta et al from Stanford.[ 35] A total of 32 patients with T3 disease were treated with irinotecan (50 mg/m2 weekly * 4), CI 5-FU (200 mg/m2/d), and 50.4 Gy. The grade 3+ acute toxicity was 28% diarrhea and 21% mucositis. The pathologic complete response rate was 37%. The largest experience has been reported by Mitchell and colleagues from Thomas Jefferson University. Forty-six patients with T3/4 rectal cancer were entered on a phase I trial of irinotecan (30 to 60 mg/m2 weekly * 4), CI 5-FU (225 to 300 mg/m2/d), and radiation therapy (45 to 54 Gy). This complicated phase I trial had both escalation and attenuation of the irinotecan, 5-FU, and radiation doses. Overall, there was a 24% pathologic complete response and a 15% clinical complete response rate. In an updated report of 67 patients, the pathologic complete response rate was 25%. Patients whose tumors have microsatellite instability had a higher complete response rate than those without microsatellite instability. The recommended dose level was irinotecan at 50 mg/m2 weekly * 4, CI 5-FU at 225 mg/m2/d, and radiation therapy at 54 Gy. This regimen is being compared to a regimen of preoperative CI 5-FU plus twice-a-day radiation in the randomized phase II Radiation Therapy Oncology Group protocol R- 0012. Levine and colleagues developed a similar regimen. Based on their phase I trial in 12 patients, the recommended schedule was irinotecan at 60 mg/m2 weekly * 4, CI 5-FU at 200 mg/m2/d, and radiation therapy at 45 Gy. The replacement to RTOG R-0012 is RTOG 0247, which is a phase II randomized comparison of preoperative combined-modality therapy with irinotecan plus capecitabine and 50.4 Gy vs oxaliplatin plus capecitabine and 50.4 Gy. Conclusions The ideal irinotecan-based preoperative combined-modality regimen has not been determined. The phase I/II trials suggest that preoperative irinotecan plus radiation therapy is most effective when combined with 5-FU. The preliminary data reveal encouraging high complete response rates following preoperative therapy. However, it should be emphasized that the higher complete response rates need to be confirmed in randomized trials. Given the advantage of CI vs bolus 5-FU in the Mayo/NCCTG 86- 47-51 postoperative rectal adjuvant trial as well as the more favorable toxicity profile of irinotecan when combined with CI 5-FU compared with bolus 5-FU, the recommended regimen for patients who receive irinotecan-based combined-modality therapy is CI 5-FU, irinotecan, and pelvic radiation. New trials examining preoperative combined-modality therapy regimens substituting capecitabine for CI 5-FU are in progress.
Dr. Minsky has received research funding from, acted as a consultant for, and served on the speaker’s bureau for Pfizer, Roche, Sanofi, Genentech, and Bristol-Myers Squibb.
1. National Institutes of Health Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. J Am Med Assoc 264:1444-1450, 1990.
2. Skibber JM, Hoff PM, Minsky BD: in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, 6th ed, pp 1271-1318. Philadelphia, Lippincott, Williams and Wilkins, 2001.
3. Bosset JF, Horiot JC, Hamers HP, et al: Postoperative pelvic radiotherapy with or without elective irradiation of para-aortic nodes and liver in rectal cancer patients: A controlled clinical trial of the EORTC Radiotherapy Group. Radiother Oncol 61:7-13, 2001.
4. Lee JHL, Lee JH, Ahn JH, et al: Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: A preliminary report. J Clin Oncol 20:1751-1758, 2002.
5. Krook JE, Moertel CG, Gunderson LL, et al: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324:709-715, 1991.
6. Smalley SR, Benedetti J, Williamson S, et al: Intergroup 0144-Phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer: Bolus 5-FU vs. prolonged venous infusion (PVI) before and after XRT + PVI vs. bolus 5-FU + leucovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV (abstract 1006). Proc Am Soc Clin Oncol 22:251, 2003.
7. Tepper JE, O’Connell MJ, Niedzwiecki D, et al: Adjuvant therapy in rectal cancer: Analysis of stage, sex, and local control-Final report of Intergroup 0114. J Clin Oncol 20:1744-1750, 2002.
8. Minsky BD, Cohen AM, Enker WE, et al: Combined modality therapy of rectal cancer: Decreased acute toxicity with the pre-operative approach. J Clin Oncol 10:1218-1224, 1992.
9. Sauer R: Adjuvant versus neoadjuvant combined modality therapy for locally advanced rectal cancer: First results of the German Rectal Cancer Study (CAO/ARO/AIO-94). Int J Radiat Oncol Biol Phys 57:S124, 2003.
10. Roh MS, Colangelo L, Wieand S, et al: Response to preoperative multimodality therapy predicts survival in patients with carcinoma of the rectum. Proc Am Soc Clin Oncol 22:247, 2004.
11. Willett CG, Badizadegan K, Ancukiewicz M, et al: Prognostic factors in stage T3N0 rectal cancer: Do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum 42:167-173, 1999.
12. Merchant NB, Guillem JG, Paty PB, et al: T3N0 rectal cancer: Results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg 3:642-647, 1999.
13. Green FL, Page DL, Fleming ID, et al (eds): AJCC Cancer Staging Manual, 6th ed, pp 113-124. New York, Springer, 2002.
14. Gunderson LL, Sargent D, Tepper J, et al: Impact of TN stage and treatment on survival and relapse in adjuvant rectal cancer pooled analysis (abstract 1008). Proc Am Soc Clin Oncol 22:251, 2003.
15. Greene FL, Stewart AK, Norton HJ: A new TNM staging strategy for node-positive (stage III) rectal cancer: An analysis of 5998 patients (abstract 1007). Proc Am Soc Clin Oncol 22:251, 2003.
16. Minsky BD: Multidisciplinary management of resectable rectal cancer. Oncology 10:1701-1714, 1996.
16a. Bosset JF, Calais G, Mineur L, et al: Does the addition of chemotherapy (CT) to preoperative radiotherapy (preop RT) increase the pathological response in patients with resected rectal cancer; report of the 22921 EORTC phase III trial. Proc Am Soc Clin Oncol 22:247, 2004.
17. Camma C, Giunta M, Fiorica F, et al: Preoperative radiotherapy for resectable rectal cancer. A meta-analysis. J Am Med Assoc 284:1008-1015, 2000.
18. Colorectal Cancer Collaborative Group: Adjuvant radiotherapy for rectal cancer: A systematic overview of 22 randomised trials involving 8507 patients. Lancet 358:1291-1304, 2001.
19. Swedish Rectal Cancer Trial: Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980- 987, 1997.
20. Kapiteijn E, Marijnen CAM, Nagtegaal ID, et al: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638-646, 2001.
21. van de Velde CJH: Preoperative radiotherapy and TME-surgery for rectal cancer: Detailed analysis in relation to quality control in a randomized trial (abstract 506). Proc Am Soc Clin Oncol 21:127a, 2002.
22. Marijnen CAM, Kapiteijn E, van de Velde CJH, et al: Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: Report of a multicenter randomized trial. J Clin Oncol 20:817-825, 2002.
23. Marijnen CAM, Nagtegaal ID, Kapiteijn E, et al: Radiotherapy does not compensate for positive resection margins in rectal cancer patients: Report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys 55:1311-1320, 2003.
24. Beets-Tan RGH, Beets GL, Vliegen RFA, et al: Accuracy of magnetic resonance imaging in prediction of tumor-free resection margin in rectal cancer surgery. Lancet 357:497- 504, 2001.
25. Graf W, Dahlberg M, Osman MM, et al: Short-term preoperative radiotherapy results in down-staging of rectal cancer: A study of 1316 patients. Radiother Oncol 43:133-137, 1997.
26. Marijnen CAM, Nagtegaal ID, Kranenbarg EK, et al: No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 19:1976-1984, 2001.
27. Francois Y, Nemoz CJ, Baulieux J, et al: Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomized trial. J Clin Oncol 17:2396-2402, 1999.
28. Sauer R, Fietkau R, Martus P, et al: Adjuvant and neoadjuvant radiochemotherapy for advanced rectal cancer: First results of the German multicenter phase-III-trial (abstract). Int J Radiat Oncol Biol Phys 48:119, 2000.
29. Wagman R, Minsky BD, Cohen AM, et al: Sphincter preservation with preoperative radiation therapy and coloanal anastomosis: Long term follow-up. Int J Radiat Oncol Biol Phys 42:51-57, 1998.
30. Rouanet P, Saint Aubert B, Lemanski C, et al: Restorative and nonrestorative surgery for low rectal cancer after high dose radiation: Long term oncologic and functional results. Dis Colon Rectum 45:305-315, 2002.
31. Hyams DM, Mamounas EP, Petrelli N, et al: A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: A progress report of the National Surgical Adjuvant Breast and Bowel Project protocol R0-3. Dis Colon Rectum 40:131-139, 1997.
32. Valentini V, Coco C, Cellini N, et al: Preoperative chemoradiation for extraperitoneal T3 rectal cancer: Acute toxicity, tumor response, and sphincter preservation. Int J Radiat Oncol Biol Phys 40:1067-1075, 1998.
33. Grann A, Feng C, Wong D, et al: Preoperative combined modality therapy for clinically resectable uT3 rectal cancer. Int J Radiat Oncol Biol Phys 49:987-995, 2001.
34. Kuvshinoff B, Maghfoor I, Miedema B, et al: Distal margin requirements after preoperative chemoradiotherapy for distal rectal carcinomas: Are < 1 cm distal margins sufficient? Ann Surg Oncol 8:163-169, 2001.
35. Mehta VK, Cho C, Ford JM, et al: Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 55:132-137, 2003.
36. Moore HG, Riedel E, Minsky BD, et al: Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined modality therapy. Ann Surg Oncol 10:80-85, 2003.
37. Grumann MM, Noack EM, Hoffman IA, et al: Comparison of quality of life in patients undergoing abdominoperineal extirpation or anterior resection for rectal cancer. Ann Surg 233:149-156, 2001.
38. Kollmorgen CF, Meagher AP, Pemberton JH, et al: The long term effect of adjuvant postoperative chemoradiotherapy for rectal cancer on bowel function. Ann Surg 220:676-682, 1994.
39. Onaitis MW, Noone RB, Fields R, et al: Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol 8:801-806, 2001.
40. Stein DE, Mahmoud NN, Anne PR, et al: Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. Dis Colon Rectum 46:448-453, 2003.
41. Janjan NA, Crane C, Feig BW, et al: Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 24:107- 112, 2001.
42. Mohiuddin M, Hayne M, Regine WF, et al: Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys 48:1075-1080, 2000.
43. Read TE, Ogunbiyi OA, Fleshman JW, et al: Neoadjuvant external beam radiation and proctectomy for adenocarcinoma of the rectum. Dis Colon Rectum 44:1778-1790, 2001.
44. Hiotis SP, Weber SM, Cohen AM, et al: Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: An analysis of 488 patients. J Am Coll Surg 194:131-136, 2002.
45. Garcia-Aguilar J, Hernandez de Anda E, Sirivongs P, et al: A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum 46:298-304, 2003.
46. Ruo L, Tickoo S, Klimstra DS, et al: Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 236:75-81, 2002.
47. Valentini V, Coco C, Picciocchi A, et al: Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long term analysis of 165 patients. Int J Radiat Oncol Biol Phys 53:664-674, 2002.
48. Luna-Perez P, Segura J, Alvarado I, et al: Specific c-K-ras gene mutations as a tumorresponse marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Ann Surg Oncol 7:727-731, 2000.
49. Villafranca E, Okruzhnov Y, Dominguez MA, et al: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19:1779-1786, 2001.
50. Esposito G, Pucciarelli S, Alaggio R, et al: p27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer. Ann Surg Oncol 8:311- 318, 2001.
51. Elsaleh H, Robbins P, Joseph D, et al: Can p53 alterations be used to predict tumor response to pre-operative chemo-radiotherapy in locally advanced rectal cancer? Radiother Oncol 56:239-244, 2000.
52. Kandioler D, Zwrtek R, Ludwig C, et al: TP53 genotype but not p53 immunohistochemical result predicts response to preop erative short-term radiotherapy in rectal cancer. Ann Surg 235:493-498, 2002.
53. Schwander O, Bruce HP, Broll R: p21, p27, cyclin D1, and p53 in rectal cancer: Immunohistology with prognostic significance? Int J Colorec Dis 17:11-19, 2002.
54. Saw RPM, Morgan M, Koorey D, et al: p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum 46:192-202, 2003.
55. Adell GCE, Zhang H, Evertsson S, et al: Apoptosis in rectal cancer: Prognosis and recurrence after preoperative radiotherapy. Cancer 91:1870-1875, 2001.
56. Rodel C, Grabenbauer GG, Papadopoulos T, et al: Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 52:294-303, 2002.
57. Giralt J, Eraso A, Armengol M, et al: Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 54:1460-1465, 2002.
58. Adell G, Zhang H, Jansson A, et al: Decreased tumor cell proliferation as an indicator of the effect of preoperative radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys 50:659-663, 2001.
59. Fernandez-Martos C, Aparicio J, Bosch C, et al: Preoperative therapy (PT) with oral uracil and tegafur (UFT) and concomitant irradiation (RT) in operable rectal cancer (RC). Preliminary results of a multicenter phase II study (abstract 590). Proc Am Soc Clin Oncol 20:148a, 2001.
60. James RD, Botwood N, Vernon CC, et al: Raltitrexed plus radiotherapy for the treatment of unresectable/recurrent rectal cancer: A phase I study. Ann Oncol 14:570-573, 2003.
61. Eric F, Marc Y, Michel D, et al: A phase I study of 5-fluorouracil continuous infusion (5- FU CI), weekly oxaliplatin (OXA) and radiotherapy (RT) in advanced rectal cancer (abstract 1381). Proc Am Soc Clin Oncol 22:344, 2003.
62. Rosenthal DI, Catalano P, Haller DG, et al: ECOG 1297: A phase I study of preoperative radiation therapy (RT) with concurrent protracted continuous infusion 5-FU and dose escalating oxaliplatin followed by surgery, adjuvant 5-FU, and leucovorin for locally advanced (T3/4) rectal adenocarcinoma (abstract 1094). Proc Am Soc Clin Oncol 22:273, 2003.
63. Gerard JP, Chapet O, Nemoz C, et al: Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: The Lyon R0-04 phase II trial. J Clin Oncol 21:1119-1124, 2003.
64. Carraro S, Roca EL, Cartelli C, et al: Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: A phase II IATTGI study. Int J Radiat Oncol Biol Phys 54:397-402, 2002.
65. Ratto C, Valentini V, Morganti AG, et al: Combined modality therapy in locally advanced primary rectal cancer. Dis Colon Rectum 46:59-67, 2003.
66. Levine EL, Gollins S, Susnerwala S, et al: Phase I/II study of irinotecan (CPT-11), 5- fluorouracil and concurrent radiotherapy for the treatment of T3-T4 locally advanced inoperable rectal cancer (abstract 1384). Proc Am Soc Clin Oncol 22:345, 2003.
67. Ranson M, Hammond LA, Ferry D, et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 20:1512-1521, 2002.
68. Dunst J, Reese T, Hoelscher T, et al: Capecitabine combined with radiotherapy as neoadjuvant treatment of locally advanced rectal cancer (abstract 1113). Proc Am Soc Clin Oncol 22:277, 2003.
69. Cunningham D, Humblet Y, Siena S, et al: Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) (abstract 1012). Proc Am Soc Clin Oncol 22:252, 2003.
70. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000.
71. Minsky BD, O’Reilly E, Wong D, et al: Daily low-dose irinotecan (CPT-11) plus pelvic irradiation as preoperative treatment of locally advanced rectal cancer (abstract). Proc Am Soc Clin Oncol 18:266a, 1999.
72. Volter V, Stupp R, Matter M, et al: Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in rectal carcinoma (abstract). Proc Am Soc Clin Oncol 20:126b, 2001.
73. Stupp R, Matter M, Volter V, et al: Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal cancer (LARC): A phase I study (abstract). Int J Radiat Oncol Biol Phys 51:11, 2001.
74. Navarro M, Dotor E, Rivera F, et al: A phase II study of irinotecan (CPT-11) and 5- fluorouracil (5-FU) concomitantly with preoperative radiotherapy (RT) in patients with locally advanced resectable rectal cancer (abstract 1235). Proc Am Soc Clin Oncol 22:308, 2003.
75. Klautke G, Kirchner R, Hopt U, et al: Continuous infusion of 5-FU and weekly irinotecan with concurrent radiotherapy as neoadjuvant treatment for locally advanced or recurrent rectal cancer (abstract 555). Proc Am Soc Clin Oncol 20:140a, 2001.
76. Mitchell EP, Anne P, Fry R, et al: Combined modality therapy of locally advanced or recurrent adenocarcinoma of the rectum: Report of a phase I trial of chemotherapy (CT) with CPT-11, 5-FU and concomitant irradiation (RT) (abstract 519). Proc Am Soc Clin Oncol 20:131a, 2001.
77. Mitchell EP, Anne PR, Fry RD, et al: Chemoradiation with CPT-11, 5-FU, in neoadjuvant treatment of locally advanced or recurrent adenocarcinoma of the rectum: A phase I/II study update (abstract 1052). Proc Am Soc Clin Oncol 22:262, 2003.
78. O’Connell MJ, Martenson JA, Weiand HS, et al: Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502-507, 1994.
79. Rothenberg MA, Meropol NJ, Poplin E, et al: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 19:3801-3807, 2001.